Cempra (CEMP) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch
February 25, 2016 7:09 AM ESTBaird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following the company's 4Q. Cempra is currently focused on completing regulatory submissions for Solithromycin in CABP and prepping for launch in 2017. As such, the company's 4Q results are... More
